Brain mets

Abstract 9063 combines data from two trials on Alectinib. There were 225 patients. The conclusion reached was that “Alectinib is effective in patients with baseline CNS mets, regardless of prior radiation treatment. Based on the low incidence of CNS progressive disease in patients without CNS mets at baseline, Alectinib may also have a potential preventative effect on patients.”

Abstract e20527 looked at 291 patients in Canada. 141 with and 150 without brain mets. 12% had ALK mutations and 88% had EGFR mutations. They found that the patients without brain mets had a median survival about 2 years longer.

This entry was posted in Brain metastases, Lung cancer, Research. Bookmark the permalink.

Leave a Reply